-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – interleukin-2
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry interleukin-2 Drug Details interleukin-2 is under development as adjuvant for treatment of graft versus...
-
Product Insights
Graft Versus Host Disease (GVHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness, and weight loss. Treatment includes immunosuppressants. The GVHD pipeline market research report provides comprehensive information on the therapeutics under development for GVHD, complete with analysis by stage of development, drug target, mechanism...
-
Product Insights
Bone Marrow Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bone Marrow Transplant Rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain and shortness of breath. The Bone Marrow Transplant Rejection - drugs in development research report provides a comprehensive overview on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis...